TMCnet News
T-Therapeutics announces oversubscribed $133 million Series B financing to achieve clinical proof-of-concept for first-in-class TCR bispecific therapies in cancer and autoimmune disease
5th November 2026; Cambridge, UK – T-Therapeutics, a biotechnology company developing next-generation T cell receptor (TCR) T cell engager (TCE) therapeutics for cancer and autoimmune diseases, today announces the closing of an oversubscribed $133 million Series B financing to fund the clinical development of its first-in-class TCR-CD3 bispecific lead programmes in oncology and autoimmune disease. The financing was co-led by Advent Life Sciences and British Business Bank with participation from other new investors, JJDC, Samsara BioCapital, M-Ventures and Eli Lilly and Company (Lilly), alongside all existing major shareholders, Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, Tencent and BGF. Proceeds from the financing will support entry into the clinic and the generation of clinical proof-of-concept data for T-Therapeutics’ two lead programmes in cancer and autoimmune diseases. Both programmes leverage the company’s unique, proprietary OpTiMus® platform, which provides an unparalleled supply of fully human TCRs, enabling access to validated, but previously undruggable, intracellular targets. T-Therapeutics’ lead oncology programme offers broad therapeutic potential across the largely untapped solid tumour space. In immunology, the company is deploying its platform to drive a novl, precision approach to immune reset, through the selective depletion of pathogenic cells that drive chronic tissue inflammation. Both programmes have the potential to address multiple indications and to meaningfully improve patient outcomes where there are currently limited treatment options. Following this financing, representatives from Advent Life Sciences, British Business Bank, JJDC and Samsara BioCapital will join T-Therapeutics’ Board as non-executive directors. Alongside the Series B financing, T-Therapeutics has further strengthened its leadership team with the appointment of Dr. Kirsty Crame as Chief Development Officer to oversee the translational and clinical development of the company’s pipeline. Dr. Crame previously served as Chief Medical Officer at Curatis AG and brings over 15 years’ experience in novel biopharmaceutical development. She led multiple early-stage clinical programmes at Medigene AG and Gadeta BV, and has particular expertise in TCR-based therapeutics. Theodora Harold, Chief Executive Officer of T-Therapeutics, said: Dominic Schmidt, General Partner at Advent Life Sciences, added: Dr. Kirsty Crame, newly appointed Chief Development Officer of T-Therapeutics, said: Contact Us T-Therapeutics ICR Healthcare About T-Therapeutics The Company is backed by expert, specialist healthcare investors Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, University of Cambridge Venture Fund, Tencent, BGF, Advent Life Sciences, British Business Bank, JJDC, Samsara BioCapital, M-Ventures, and Lilly.
|

